TORNALATE
LOE ApproachingNDAINHALATIONAEROSOL, METERED
Approved
Dec 1984
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TORNALATE is a metered-dose inhaled aerosol approved in 1984 for respiratory indications. The specific mechanism of action and therapeutic class are not documented in available data, limiting clinical context. It is a small-molecule product delivered via inhalation route.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100), suggesting declining team investment and potential restructuring of commercial resources.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings reflect the mature, LOE-approaching status of TORNALATE, indicating minimal active hiring and limited career development opportunity. Assignment to this product portfolio suggests focus on legacy brand management, cost optimization, or transition planning rather than growth initiatives.
Brand ManagerField Sales Representative
Worked on TORNALATE at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.